CMP DEV LLC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CMP DEV LLC, and when can generic versions of CMP DEV LLC drugs launch?
CMP DEV LLC has six approved drugs.
There are twenty US patents protecting CMP DEV LLC drugs.
There are sixteen patent family members on CMP DEV LLC drugs in nine countries and fifty-two supplementary protection certificates in eleven countries.
Summary for CMP DEV LLC
| International Patents: | 16 |
| US Patents: | 20 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
Drugs and US Patents for CMP DEV LLC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | LIQREV | sildenafil citrate | SUSPENSION;ORAL | 214952-001 | Apr 28, 2023 | RX | Yes | Yes | 11,337,979 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | 11,925,704 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522-001 | Jun 17, 2022 | RX | Yes | Yes | 11,382,917 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | AB | RX | Yes | Yes | 11,491,166 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Cmp Dev Llc | LIQREV | sildenafil citrate | SUSPENSION;ORAL | 214952-001 | Apr 28, 2023 | RX | Yes | Yes | 11,759,468 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CMP DEV LLC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017212409 | ⤷ Try a Trial |
| China | 111683683 | ⤷ Try a Trial |
| Morocco | 50320 | ⤷ Try a Trial |
| Canada | 3086881 | ⤷ Try a Trial |
| Japan | 2021509114 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CMP DEV LLC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1507558 | 12C0033 | France | ⤷ Try a Trial | PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: CH - 6167801 20110705 |
| 0678503 | C300499 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114 |
| 0720599 | 300689 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| 0503785 | CA 2011 00026 | Denmark | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
| 0247633 | 97C0103 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
